United States Patent [19]

Desai et al.

- [54] PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF
- [75] Inventors: Neil P. Desai, Los Angeles; Chunlin Tao, Beverly Hills; Andrew Yang, Rosemead; Leslie Louie, Montebello; Tianli Zheng; Zhiwen Yao, both of Culver City; Patrick Soon-Shiong, Los Angeles, all of Calif.; Shlomo Magdassi, Jerusalem, Israel
- [73] Assignee: Vivorx Pharmaceuticals, Inc., Santa Monica, Calif.
- [21] Appl. No.: 08/720,756
- [22] Filed: Oct. 1, 1996

Related U.S. Application Data

- [60] Continuation-in-part of application No. 08/412,726, Mar. 29, 1995, Pat. No. 5,560,933, which is a division of application No. 08/023,698, Feb. 22, 1993, Pat. No. 5,439,686.
- [51] Int. Cl.⁶ A61K 9/14
- [52] U.S. Cl. 424/489; 424/450; 424/465;
- 424/451; 424/439

[56] References Cited

U.S. PATENT DOCUMENTS

3,959,457	5/1976	Speaker et al
4,073,943	2/1978	Wretlind et al
4,247,406	1/1981	Widder et al
4.572.203	2/1986	Feinstein .

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

0 129 619 A1 1/1985 European Pat. Off. .

DOCKE

RM

03003910390A

[11] Patent Number: 5,916,596

[45] Date of Patent: Jun. 29, 1999

0 295 941 A2 12/1988 European Pat. Off. . 0 391 518 A2 2/1990 European Pat. Off.

(List continued on next page.)

OTHER PUBLICATIONS

Burgess et al., "Potential use of albumin microspheres as a drug delivery system. I. Preparation and in vitro release of steroids," *International Journal of Pharmaceutics*, 39:129–136 (1987).

(List continued on next page.)

Primary Examiner—Neil S. Levy


Assistant Examiner-William E. Benston, Jr.

Attorney, Agent, or Firm—Gray, Cary, Ware & Freidenrich; Stephen E. Reiter

[57] ABSTRACT

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

31 Claims, 2 Drawing Sheets



.

U.S. PATENT DOCUMENTS

4,671,954	6/1987	Goldberg et al
4,718,433	1/1988	Feinstein .
4,789,550	12/1988	Hommel et al
4,844,882	7/1989	Widder et al
5,059,699	10/1991	Kingston et al 549/511
5,110,606	5/1992	Geyer et al
5,145,684	9/1992	Liversidge et al 424/489
5,362,478	11/1994	Desai et al 424/9
5,439,686	8/1995	Desai et al 424/451
5,498,421	3/1996	Grinstaff et al 424/450
5,505,932	4/1996	Gristaff et al 424/9.3
5,508,021	4/1996	Grinstaff et al 424/9.322
5,512,268	4/1996	Grinstaff et al 424/9.322
5,560,933	10/1996	Soon-Shing et al 424/489
5,650,156	7/1997	Grinstaff et al 424/400
5,665,382	9/1997	Grinstaff et al 424/450

FOREIGN PATENT DOCUMENTS

0 418 153 A1 3/1991 European Pat. Off
0 190 050 B1 5/1991 European Pat. Off 0 213 303 B1 9/1991 European Pat. Off
2660556 10/1991 France . WO 85/00011 1/1985 WIPO .
WO 87/01035 2/1988 WIPO . WO 88/01506 3/1988 WIPO . WO 88/07365 10/1988 WIPO .
WO 89/03674 5/1989 WIPO . WO 90/13285 11/1990 WIPO .
WO 90/13780 11/1990 WIPO . WO 91/15947 10/1991 WIPO . WO 94/10980 5/1994 WIPO .

OTHER PUBLICATIONS

Chen et al., "Comparison of albumin and casein microspheres as a carrier for doxorubicin," J. Pharm. Pharmacol., 39:978–985 (1987).

Feinstein et al., "Two–Dimensional Constrast Echocardiography. I. In Vitro Development and Quantitative Analysis of Echo Contrast Agents," *JACC*, 3(1):14–20 (1984).

Grinstaff & Suslick, "Nonaqueous Liquid Filled Microcapsules," *Polym. Prepr.*, 32:255–256 (1991).

Gupta et al., "Albumin microspheres. III. Synthesis and characterization of microspheres containing adriamycin and magnetite," *International Journal of Pharmaceutics*, 43:167–177 (1988).

Ishizaka et al., "Preparation of Egg Albumin Microcapsules and Microspheres," *Journal of Pharmaceutical Sciences*, 70(4):358–363 (1981).

Klibanov et al., "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes," *FEBS*, 268(1):235–237 (1990).

Koenig & Meltzer, "Effect of Viscosity on the Size of Microbubbles Generated for Use as Echocardiographic Contrast Agents," *Journal of Cardiovascular ultrasonography*, 5(1):3–4 (1986).

Molecular Biosystems, Inc., "ALBUNEX—Preclinical Investigator's Package".

DOCKE.

RM

Moseley et al., "Microbubbles: A Novel MR Susceptibility Contrast Agent," 10th Annual Meeting of Society of Magnetic Resonance in Medicine (1991).

Suslick & Grinstaff, "Protein Microencapsulation of Nonaqueous Liquids," J. Am. Chem. Soc., 112(21):7807–7809 (1990).

Willmott & Harrison, "Characterisation of freeze-dried albumin microspheres containing the anti-cancer drug adriamycin," *International Journal of Pharmaceutics*, 43:161–166 (1988).

——, "Serum Albumin Beads: An Injectable, Biodegradable System for the Sustained Release of Drugs," *Science*, 213(10):233–235 (1981).

Bazile et. al., "Body distribution of fully biodegeradable [¹⁴C]–poly(latic acid) nanoparticles coated with albumin after parenteral adminstration to rats" *Biomaterials*, 13:1093–1102 (1992).

Boury et al., "Dilatational Properties of Absorbed Poly(D, L-lactide) and Bovine Serum Albumin Monolayers at the Dichloromethane/Water Interface" *Langmuir*, 11:1636–1644 (1995).

Calvo et al., "Comparative in Vitro Evaluation of Several Colloidal Systems, Nanoparticles, Nanocapsules, and Nanoemulsions, as Ocular Drug Carriers" *J. Pharm. Sci.*, 85(5):530–536 (1996).

Cavalier et al., "The formation and characterization of hydrocortisone-loaded poly((+_)-lactide) microspheres" J. Pharm. Pharmacol., 38:249–253 (1985).

Kumar et al., "Binding of Taxol to Human Plasma, Albumin and—Acid Glycoprotein" *Research Communications in Chemical Pathology and Pharmacology*, 80(3):337–344 (1993).

Lee et al., "Serum Albumin Beads: An Injectable, Biodegradable System for the Sustained Release of Drugs" *Science*, 213:233–235 (1981).


Leucuta et al., "Albumin microspheres as a drug delivery system for epirubicin: pharmaceutical, pharmacokinetic and biological aspects" *International Journal of Pharmaceutics*, 41:213–217 (1988).


Liversideg–Merisko et al., "Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticacer Drugs" *Pharmaceutical Research*, 13(2):272–278 (1996).

Mathew et al., "Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity" *J. Med. Chem.*, 35:145–151 (1992).

Norton et al., Abstracts of the 2nd National Cancer Institute Workshop on Taxol & Taxus, Sep. 23–24, 1992).

Wani et al., "Plant Antitumor Agents. VI. The Isolation and Structure of Toxol, a Novel Antileukemic and Antitumor Agents from *Taxus brevifolia*^{1,2}" *J. Am. Chem. Soc.*, 93:2325–2327 (1971).





DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

10

PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF

RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 08/412,726, filed Mar. 29, 1995, now issued as U.S. Pat. No. 5,560,933, which is, in turn, a divisional of U.S. Ser. No. 08/023,698, filed Feb. 22, 1993, now issued as U.S. Pat. No. 5,439,686, the entire contents of both of which are hereby incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

The present invention relates to methods for the production of particulate vehicles for the intravenous administration of pharmacologically active agents, as well as novel compositions produced thereby. In a particular aspect, the 20 invention relates to methods for the in vivo delivery of substantially water insoluble pharmacologically active agents (e.g., the anticancer drug taxol). In another aspect, dispersible colloidal systems containing water insoluble pharmacologically active agents are provided. The sus- 25 pended particles are encased in a polymeric shell formulated from a biocompatible polymer, and have a diameter of less than about 1 micron. Invention colloidal systems are prepared without the use of conventional surfactant or any polymeric core matrix. In a presently preferred aspect of the 30 invention, there is provided a method for preparation of extremely small particles which can be sterile-filtered. The polymeric shell contains particles of pharmacologically active agent, and optionally a biocompatible dispersing agent in which pharmacologically active agent can be either dissolved or suspended. Thus, the invention provides a drug delivery system in either liquid form or in the from of a redispersible powder. Either form provides both immediately bioavailable drug molecules (i.e., drug molecules which are molecularly bound to a protein), and pure drug 40 particles coated with a protein.

BACKGROUND OF THE INVENTION

Intravenous drug delivery permits rapid and direct equilibration with the blood stream which carries the medication to the rest of the body. To avoid the peak serum levels which are achieved within a short time after intravascular injection, administration of drugs carried within stable carriers would allow gradual release of the drugs inside the intravascular compartment following a bolus intravenous injection of the therapeutic nanoparticles.

Injectable controlled-release nanoparticles can provide a pre-programmed duration of action, ranging from days to weeks to months from a single injection. They also can offer several profound advantages over conventionally administered medicaments, including automatic assured patient compliance with the dose regimen, as well as drug targeting to specific tissues or organs (Tice and Gilley, *Journal of Controlled Release* 2:343–352 (1985)). 60

Microparticles and foreign bodies present in the blood are generally cleared from the circulation by the "blood filtering organs", namely the spleen, lungs and liver. The particulate matter contained in normal whole blood comprises red blood cells (typically 8 microns in diameter), white blood cells (typically 6–8 microns in diameter), and platelets (typically 1–3 microns in diameter). The microcirculation in most

DOCKE.

organs and tissues allows the free passage of these blood cells. When microthrombii (blood clots) of size greater than 10–15 microns are present in circulation, a risk of infarction or blockage of the capillaries results, leading to ischemia or oxygen deprivation and possible tissue death. Injection into the circulation of particles greater than 10–15 microns in diameter, therefore, must be avoided. A suspension of particles less than 7–8 microns, is however, relatively safe and has been used for the delivery of pharmacologically active agents in the form of liposomes and emulsions, nutritional agents, and contrast media for imaging applications.

The size of particles and their mode of delivery determines their biological behavior. Strand et al. (in Microspheres-Biomedical Applications, ed. A. Rembaum, 15 pp 193-227, CRC Press (1988)) have described the fate of particles to be dependent on their size. Particles in the size range of a few nanometers (nm) to 100 nm enter the lymphatic capillaries following interstitial injection, and phagocytosis may occur within the lymph nodes. After intravenous/intraarterial injection, particles less than about 2 microns will be rapidly cleared from the blood stream by the reticuloendothelial system (RES), also known as the mononuclear phagocyte system (MPS). Particles larger than about 7 microns will, after intravenous injection, be trapped in the lung capillaries. After intraarterial injection, particles are trapped in the first capillary bed reached. Inhaled particles are trapped by the alveolar macrophages.

Pharmaceuticals that are water-insoluble or poorly watersoluble and sensitive to acid environments in the stomach cannot be conventionally administered (e.g., by intravenous injection or oral administration). The parenteral administration of such pharmaceuticals has been achieved by emulsification of the oil solubilized drug with an aqueous liquid (such as normal saline) in the presence of surfactants or emulsion stabilizers to produce stable microemulsions. These emulsions may be injected intravenously, provided the components of the emulsion are pharmacologically inert. U.S. Pat. No. 4,073,943 describes the administration of water-insoluble pharmacologically active agents dissolved in oils and emulsified with water in the presence of surfactants such as egg phosphatides, pluronics (copolymers of polypropylene glycol and polyethylene glycol), polyglycerol oleate, etc. PCT International Publication No. W085/ 00011 describes pharmaceutical microdroplets of an anaesthetic coated with a phospholipid such as dimyristoyl phosphatidylcholine having suitable dimensions for intradermal or intravenous injection.

An example of a water-insoluble drug is taxol, a natural product first isolated from the Pacific Yew tree, *Taxus* 50 brevifolia, by Wani et al. (J. Am. Chem. Soc. 93:2325 (1971)). Among the antimitotic agents, taxol, which contains a diterpene carbon skeleton, exhibits a unique mode of action on microtubule proteins responsible for the formation of the mitotic spindle. In contrast with other antimitotic 55 agents such as vinblastine or colchicine, which prevent the assembly of tubulin, taxol is the only plant product known to inhibit the depolymerization process.

Taxol, a naturally occurring diterpenoid, has been shown to have significant antineoplastic and anticancer effects in drug-refractory ovarian cancer. Taxol has shown excellent antitumor activity in a wide variety of tumor models such as the B16 melanoma, L1210 leukemias, MX-1 mammary tumors, and CS-1 colon tumor xenografts. Several recent press releases have termed taxol as the new anticancer wonder-drug. Indeed, taxol has recently been approved by the Federal Drug Administration for treatment of ovarian

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.